2016 Annual Meeting | Invited Science: Movement Disorders
| 03:30 PM - 03:50 PM |
Microglial Dysfunction Plays a Critical Role in Huntington’s Disease Pathogenesis
Blair Leavitt, MD |
|
| 03:50 PM - 04:10 PM |
PREDICT-PD: Identifying Risk of Parkinson’s Disease in the Community
Alastair J. Noyce, MBBS |
|
| 04:10 PM - 04:30 PM |
Glucocerebrosidase Activity in Parkinson’s Disease With and Without GBA Mutations
Roy Alcalay, MD |
|
| 04:30 PM - 04:50 PM |
Tau-PET Imaging in Progressive Supranuclear Palsy Using [18F] AV-1451
Daniel Schonhaut |
|
| 04:50 PM - 05:10 PM |
Inhaled Levodopa (CVT-301) Provides Rapid Improvement of OFF States in Parkinson’s Disease
Peter A. LeWitt, MD |
|
| 05:10 PM - 05:30 PM |
Stable Levodopa Plasma Levels With ND0612 (Levodopa/Carbidopa for Subcutaneous Infusion) in Parkinson’s Disease (PD) Patients With Motor Fluctuations
Sheila Oren, MD, MBA |
| Joseph Jankovic, MD, FAAN | Dr. Jankovic has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Revance. Dr. Jankovic has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Revance, Allergan. The institution of Dr. Jankovic has received research support from Baylor College of Medicine. Dr. Jankovic has received research support from Abbvie. The institution of Dr. Jankovic has received research support from Abbvie. |
| Peter A. LeWitt, MD | Dr. LeWitt has received personal compensation for serving as an employee of Supernus. Dr. LeWitt has received personal compensation for serving as an employee of Amneal. Dr. LeWitt has received personal compensation for serving as an employee of Hoffmann-La Roche - Genentech. Dr. LeWitt has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Mitsubishi Tanabe-NeuroDerm Neuropharma. Dr. LeWitt has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Bukwang Pharmaceuticals. Dr. LeWitt has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for Neurocrine. Dr. LeWitt has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Supernus. The institution of Dr. LeWitt has received research support from Michael J Fox Foundation. |
| Blair Leavitt, MD | Dr. Leavitt has received personal compensation in the range of $50,000-$99,999 for serving as a Consultant for Incisive Genetics. Dr. Leavitt has received personal compensation in the range of $10,000-$49,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Roche. Dr. Leavitt has received personal compensation in the range of $5,000-$9,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Novartis. Dr. Leavitt has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for PTC Therapeutics. Dr. Leavitt has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Design TX. Dr. Leavitt has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for ReMix Tx. Dr. Leavitt has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Sintetica. Dr. Leavitt has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Triplet Tx. Dr. Leavitt has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Takeda. Dr. Leavitt has received personal compensation in the range of $10,000-$49,999 for serving as an officer or member of the Board of Directors for Incisive Genetics. Dr. Leavitt has received personal compensation in the range of $500-$4,999 for serving as an Editor, Associate Editor, or Editorial Advisory Board Member for Journal of Huntington's Disease. Dr. Leavitt has stock in Incisive Genetics. Dr. Leavitt has stock in SRNAlytics. The institution of Dr. Leavitt has received research support from CIHR. The institution of Dr. Leavitt has received research support from HSC. The institution of Dr. Leavitt has received research support from Brain Canada. The institution of Dr. Leavitt has received research support from NMIN. Dr. Leavitt has received intellectual property interests from a discovery or technology relating to health care. |
| Deborah Hall, MD, PhD, FAAN | Dr. Hall has received personal compensation in the range of $10,000-$49,999 for serving as an Editor, Associate Editor, or Editorial Advisory Board Member for 好色先生. Dr. Hall has received personal compensation in the range of $500-$4,999 for serving as an Editor, Associate Editor, or Editorial Advisory Board Member for Elsevier - Parkinsonism and Related Disorders. Dr. Hall has received personal compensation in the range of $500-$4,999 for serving as an Editor, Associate Editor, or Editorial Advisory Board Member for Annals of Neurology. The institution of Dr. Hall has received research support from Parkinson's Foundation. The institution of Dr. Hall has received research support from CHDI. The institution of Dr. Hall has received research support from Uniqure. The institution of Dr. Hall has received research support from NIH. |
| Roy Alcalay, MD | Dr. Alcalay has received personal compensation in the range of $10,000-$49,999 for serving as a Consultant for Genzyme/Sanofi. Dr. Alcalay has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Biogen. Dr. Alcalay has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Gain Therapeutics. Dr. Alcalay has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Vanqua Bio. Dr. Alcalay has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Takeda. Dr. Alcalay has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Biohaven. Dr. Alcalay has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Capsida. Dr. Alcalay has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Servier. The institution of Dr. Alcalay has received research support from Michael J. Fox Foundation. The institution of Dr. Alcalay has received research support from Parkinson's Foundation. The institution of Dr. Alcalay has received research support from Silverstein Foundation. Dr. Alcalay has received personal compensation in the range of $50,000-$99,999 for serving as a Consultant with Parkinson's Foundation. |
| Alastair J. Noyce, MBBS | Dr. Noyce has received personal compensation in the range of $10,000-$49,999 for serving as a Consultant for uMed. Dr. Noyce has received personal compensation in the range of $10,000-$49,999 for serving as a Consultant for AbbVie. Dr. Noyce has received personal compensation in the range of $10,000-$49,999 for serving on a Scientific Advisory or Data Safety Monitoring board for AstraZeneca. Dr. Noyce has received personal compensation in the range of $5,000-$9,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Charco NeuroTech. Dr. Noyce has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Alchemab. Dr. Noyce has received personal compensation in the range of $500-$4,999 for serving on a Speakers Bureau for MDS. Dr. Noyce has received personal compensation in the range of $500-$4,999 for serving on a Speakers Bureau for BIAL. Dr. Noyce has received personal compensation in the range of $10,000-$49,999 for serving as an officer or member of the Board of Directors for Oxford Pharmagenesis. Dr. Noyce has received personal compensation in the range of $10,000-$49,999 for serving as an Expert Witness for AstraZeneca. The institution of Dr. Noyce has received research support from Solvemed. The institution of Dr. Noyce has received research support from Alchemab. |
| Sheila Oren, MD, MBA | Sheila Oren, MD, MBA has received personal compensation for serving as an employee of Neuroderm. Sheila Oren, MD, MBA has received personal compensation in the range of $0-$499 for serving as a Consultant for Neuroderm. |
| Daniel Schonhaut | No disclosure on file |